GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Cyclically Adjusted FCF per Share

Oncolytics Biotech (Oncolytics Biotech) Cyclically Adjusted FCF per Share : $-0.81 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Oncolytics Biotech's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.062. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.81 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 18.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Oncolytics Biotech was 18.20% per year. The lowest was -2.10% per year. And the median was 7.75% per year.

As of today (2024-04-27), Oncolytics Biotech's current stock price is $1.09. Oncolytics Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-0.81. Oncolytics Biotech's Cyclically Adjusted Price-to-FCF of today is .


Oncolytics Biotech Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Oncolytics Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Cyclically Adjusted FCF per Share Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.72 -1.55 -1.38 -0.99 -0.81

Oncolytics Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.99 -0.91 -0.90 -0.83 -0.81

Competitive Comparison of Oncolytics Biotech's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Oncolytics Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Cyclically Adjusted Price-to-FCF falls into.



Oncolytics Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncolytics Biotech's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.062/125.4675*125.4675
=-0.062

Current CPI (Dec. 2023) = 125.4675.

Oncolytics Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.621 98.604 -0.790
201406 -0.586 99.473 -0.739
201409 -0.441 99.394 -0.557
201412 -0.302 98.367 -0.385
201503 -0.209 99.789 -0.263
201506 -0.345 100.500 -0.431
201509 -0.175 100.421 -0.219
201512 -0.256 99.947 -0.321
201603 -0.184 101.054 -0.228
201606 -0.162 102.002 -0.199
201609 -0.182 101.765 -0.224
201612 -0.225 101.449 -0.278
201703 -0.231 102.634 -0.282
201706 -0.260 103.029 -0.317
201709 -0.176 103.345 -0.214
201712 -0.170 103.345 -0.206
201803 -0.240 105.004 -0.287
201806 0.027 105.557 0.032
201809 -0.165 105.636 -0.196
201812 -0.190 105.399 -0.226
201903 -0.138 106.979 -0.162
201906 -0.177 107.690 -0.206
201909 -0.151 107.611 -0.176
201912 -0.202 107.769 -0.235
202003 -0.076 107.927 -0.088
202006 -0.117 108.401 -0.135
202009 -0.111 108.164 -0.129
202012 -0.101 108.559 -0.117
202103 -0.089 110.298 -0.101
202106 -0.102 111.720 -0.115
202109 -0.057 112.905 -0.063
202112 -0.091 113.774 -0.100
202203 -0.088 117.646 -0.094
202206 -0.094 120.806 -0.098
202209 -0.055 120.648 -0.057
202212 -0.073 120.964 -0.076
202303 -0.089 122.702 -0.091
202306 -0.099 124.203 -0.100
202309 -0.064 125.230 -0.064
202312 -0.062 125.468 -0.062

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Oncolytics Biotech  (NAS:ONCY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Oncolytics Biotech Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry
Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.

Oncolytics Biotech (Oncolytics Biotech) Headlines

From GuruFocus